Wyeth has acquired global rights to Mochida Pharmaceutical's preclinical transient receptor potential vanilloid sub-family 1 (TRPV-1) antagonist molecule for treating pain, the companies announced Jan 9. In retum , Tokyo-based Mochida will be paid developmental milestones, an up-front fee and royalties on future sales. |
|
|
 Wyeth Gets Exclusive License for Mochida’s Painkiller Drug |
